

# Erratum to: “Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients: a frailty subgroup analysis of the IMROZ trial”

Salomon Manier,<sup>1</sup> Meletios-Athanasios Dimopoulos,<sup>2,3</sup> Xavier P. Leleu,<sup>4</sup> Philippe Moreau,<sup>5</sup> Michele Cavo,<sup>6</sup> Hartmut Goldschmidt,<sup>7</sup> Robert Z. Orlowski,<sup>8</sup> Muriel Tron,<sup>9</sup> Christina Tekle,<sup>10</sup> Marie-France Brégeault,<sup>11</sup> Andrea T. Shafer,<sup>10</sup> Meral Beksac<sup>12</sup> and Thierry Facon<sup>1,13</sup>


<sup>1</sup>Department of Hematology, University Hospital Center of Lille, Lille, France; <sup>2</sup>Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece; <sup>3</sup>Department of Medicine, Korea University, Seoul, South Korea; <sup>4</sup>Service d’Hématologie et Thérapie Cellulaire, CHU and CIC Inserm 1402, Poitiers Cedex, France; <sup>5</sup>Department of Hematology, University Hospital Hotel-Dieu, Nantes, France; <sup>6</sup>Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy; <sup>7</sup>Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany; <sup>8</sup>Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; <sup>9</sup>Sanofi, Vitry, France; <sup>10</sup>Sanofi, Cambridge, MA, USA; <sup>11</sup>Sanofi R&D, Vitry-sur-Seine, France; <sup>12</sup>Istinye University Ankara Liv Hospital, Ankara, Turkey and <sup>13</sup>French National Academy of Medicine, Paris, France

**Correspondence:** S. Manier  
salomon.manier@chu-lille.fr


**Received:** February 24, 2026.

**Accepted:** February 24, 2026.


<https://doi.org/10.3324/haematol.2026.289422>

Published under a CC BY license 

An issue was identified with the labeling of the IsaVRd and VRd arms in Figure 3A, B.<sup>1</sup> The revised and corrected Figure 3 is shown below.



Continued on following page.



**Figure 3. Quality of life as measured by EORTC-QLQ-C30 in the frail and non-frail subgroups.** (A) Frail subgroup. (B) Non-frail subgroup. d: dexamethasone; EORTC-QLQ-C30: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30; EOT: end of treatment; Fu: follow-up; Isa: isatuximab; R: lenalidomide; V: bortezomib.

## References

1. Manier S, Dimopoulos M-A, Leleu XP et al. Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplantineligible newly diagnosed multiple myeloma patients: a frailty subgroup analysis of the IMROZ trial. *Haematologica*. 2025;110(9):2139-2150.